Johnson & Johnson: Number of Employees 2010-2023 | JNJ

Interactive chart of Johnson & Johnson (JNJ) annual worldwide employee count from 2010 to 2023.
  • Johnson & Johnson total number of employees in 2022 was 155,800, a 9.95% increase from 2021.
  • Johnson & Johnson total number of employees in 2021 was 141,700, a 5.35% increase from 2020.
  • Johnson & Johnson total number of employees in 2020 was 134,500, a 1.74% increase from 2019.
  • Johnson & Johnson total number of employees in 2019 was 132,200, a 2.15% decline from 2018.
Johnson & Johnson Annual Number of Employees
2022 155,800
2021 141,700
2020 134,500
2019 132,200
2018 135,100
2017 134,000
2016 126,400
2015 127,100
2014 126,500
2013 128,100
2012 127,600
2011 117,900
2010 114,000
2009 115,500
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $387.763B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $726.876B 121.04
Novo Nordisk (NVO) Denmark $548.511B 45.19
Merck (MRK) United States $326.787B 86.02
AbbVie (ABBV) United States $316.181B 16.11
Novartis AG (NVS) Switzerland $218.637B 15.15
AstraZeneca (AZN) United Kingdom $205.648B 18.22
Pfizer (PFE) United States $151.842B 14.69
Sanofi (SNY) $121.951B 10.98
Innoviva (INVA) United States $0.985B 8.88